Normal tissue studies in radiation oncology: A systematic review of highly cited articles and citation patterns

Nieder,Carsten; Andratschke,Nicolaus  H.; Grosu,Anca  L.

doi:10.3892/ol.2014.2252

Normal tissue studies in radiation oncology: A systematic review of highly cited articles and citation patterns

Authors:
- Carsten Nieder
- Nicolaus H. Andratschke
- Anca L. Grosu
View Affiliations

Affiliations: Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø 8092, Norway, Department of Radiation Oncology, University Hospital Rostock, Rostock D‑18059, Germany, Department of Radiation Oncology, University Hospital Freiburg, Freiburg D‑79106, Germany
Published online on: June 13, 2014 https://doi.org/10.3892/ol.2014.2252
Pages: 972-976

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Radiation therapy is one of the cornerstones of modern multidisciplinary cancer treatment. Normal tissue tolerance is critical as radiation‑induced side effects may compromise organ function and quality of life. The importance of normal tissue research is reflected by the large number of scientific articles, which have been published between 2006 and 2010. The present study identified important areas of research as well as seminal publications. The article citation rate is among the potential indicators of scientific impact. Highly cited articles, arbitrarily defined as those with ≥15 citations, were identified via a systematic search of the citation database, Scopus. Up to 608 articles per year were published between 2006 and 2010, however, <10% of publications in each year accumulated ≥15 citations. This figure is notably low, when compared with other oncology studies. A large variety of preclinical and clinical topics, including toxicity prediction, the dose‑volume relationship and radioprotectors, accumulated ≥15 citations. However, clinical prevention or mitigation studies were underrepresented. The following conclusion may be drawn from the present study; despite the improved technology that has resulted in superior dose distribution, clinical prevention or mitigation studies are critical and must receive higher priority, funding and attention.

View Figures

View References

1	Moding EJ, Kastan MB and Kirsch DG: Strategies for optimizing the response of cancer and normal tissues to radiation. Nat Rev Drug Discov. 12:526–542. 2013.
2	Löfdahl E, Berg G, Johansson KA, et al: Compromised quality of life in adult patients who have received a radiation dose towards the basal part of the brain. A case-control study in long-term survivors from cancer in the head and neck region. Radiat Oncol. 7:1792012.
3	Raabe A, Derda K, Reuther S, et al: Association of single nucleotide polymorphisms in the genes ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with risk of severe erythema after breast conserving radiotherapy. Radiat Oncol. 7:652012.
4	Mangoni M, Vozenin MC, Biti G and Deutsch E: Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: hurdles might be ahead. Br J Cancer. 107:308–314. 2012.
5	Nieder C, Jeremic B, Astner S and Molls M: Radiotherapy-induced lung toxicity: risk factors and prevention strategies. Anticancer Res. 23:4991–4998. 2003.
6	Nieder C, Andratschke N and Astner ST: Experimental concepts for toxicity prevention and tissue restoration after central nervous system irradiation. Radiat Oncol. 2:232007.
7	Nieder C, Astner ST, Grosu AL and Molls M: Evaluation of late neurologic adverse events in patients with brain metastases from non-small cell lung cancer. Anticancer Res. 27:1701–1704
8	Young NS, Ioannidis JPA and Al-Ubaydli O: Why current publication practices may distort science. PLoS Med. 5:e2012008.
9	Kanaan Z, Galandiuk S, Abby M, et al: The value of lesser-impact-factor surgical journals as a source of negative and inconclusive outcomes reporting. Ann Surg. 253:619–623. 2011.
10	Durieux V and Gevenois PA: Bibliometric indicators: quality measurements of scientific publication. Radiology. 255:342–351. 2010.
11	Radicchi F, Fortunato S and Castellano C: Universality of citation distributions: toward an objective measure of scientific impact. Proc Natl Acad Sci USA. 105:17268–17272. 2008.
12	Vinkler P: Relations of relative scientometric indicators. Scientometrics. 58:687–694. 2003.
13	Nieder C, Astner ST and Grosu AL: Glioblastoma research 2006–2010: pattern of citation and systematic review of highly cited articles. Clin Neurol Neurosurg. 114:1207–1210. 2012.
14	Bentzen SM: Preventing or reducing late side effects of radiation therapy: Radiobiology meets molecular pathology. Nat Rev Cancer. 6:702–713. 2006.
15	François S, Bensidhoum M, Mouiseddine M, et al: Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: A study of their quantitative distribution after irradiation damage. Stem Cells. 24:1020–1029. 2006.
16	Kong FM, Hayman JA, Griffith KA, et al: Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys. 65:1075–1086. 2006.
17	Wazer DE, Kaufman S, Cuttino L, DiPetrillo T and Arthur DW: Accelerated partial breast irradiation: an analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose-rate interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 64:489–495. 2006.
18	Braam PM, Terhaard CH, Roesink JM and Raaijmakers CP: Intensity-modulated radiotherapy significantly reduces xerostomia compared with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 66:975–980. 2006.
19	Bentzen SM and Trotti A: Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol. 25:4096–4103. 2007.
20	Kouvaris JR, Kouloulias VE and Vlahos LJ: Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist. 12:738–747. 2007.
21	Söhn M, Yan D, Liang J, et al: Incidence of late rectal bleeding in high-dose conformal radiotherapy of prostate cancer using equivalent uniform dose-based and dose-volume-based normal tissue complication probability models. Int J Radiat Oncol Biol Phys. 67:1066–1073. 2007.
22	Shirazi A, Ghobadi G and Ghazi-Khansari M: A radiobiological review on melatonin: a novel radioprotector. J Radiat Res. 48:263–272. 2007.
23	Giotopoulos G, Symonds RP, Foweraker K, et al: The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes. Br J Cancer. 96:1001–1007. 2007.
24	Kirkpatrick JP, Meyer JJ and Marks LB: The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol. 18:240–243. 2008.
25	Fiorino C, Fellin G, Rancati T, et al: Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys. 70:1130–1137. 2008.
26	Mayer R and Sminia P: Reirradiation tolerance of the human brain. Int J Radiat Oncol Biol Phys. 70:1350–1360. 2008.
27	Clarke RE, Tenorio LM, Hussey JR, et al: Hyperbaric oxygen treatment of chronic refractory radiation proctitis: a randomized and controlled double-blind crossover trial with long-term follow-up. Int J Radiat Oncol Biol Phys. 72:134–143. 2008.
28	Burri RJ, Stock RG, Cesaretti JA, et al: Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiat Res. 170:49–59. 2008.
29	Fiorino C, Valdagni R, Rancati T and Sanguineti G: Dose-volume effects for normal tissues in external radiotherapy: pelvis. Radiother Oncol. 93:153–167. 2009.
30	Barnett GC, West CM, Dunning AM, et al: Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer. 9:134–142. 2009.
31	Weiss JF and Landauer MR: History and development of radiation-protective agents. Int J Radiat Biol. 85:539–573. 2009.
32	Zhao W and Robbins ME: Inflammation and chronic oxidative stress in radiation-induced late normal tissue injury: therapeutic implications. Curr Med Chem. 16:130–143. 2009.
33	Yuan X, Liao Z, Liu Z, et al: Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol. 27:3370–3378. 2009.
34	Michalski JM, Gay H, Jackson A, et al: Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys. 76(Suppl 3): S123–S129. 2010.
35	Bentzen SM, Constine LS, Deasy JO, et al: Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 76(Suppl 3): S3–S9. 2010.
36	Citrin D, Cotrim AP, Hyodo F, et al: Radioprotectors and mitigators of radiation-induced normal tissue injury. Oncologist. 15:360–371. 2010.
37	Yarnold J and Brotons MC: Pathogenetic mechanisms in radiation fibrosis. Radiother Oncol. 97:149–161. 2010.
38	Gulliford SL, Foo K, Morgan RC, et al: Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys. 76:747–754. 2010.
39	Nieder C: Highly cited German research contributions to the fields of radiation oncology, biology, and physics: focus on collaboration and diversity. Strahlenther Onkol. 188:865–872. 2012.
40	Kondziolka D: Citation measures in stereotactic radiosurgery: publication across a discipline. Stereotact Funct Neurosurg. 89:56–61. 2011.
41	Stringer MJ, Sales-Pardo M and Nunes Amaral LA: Statistical validation of a global model for the distribution of the ultimate number of citations accrued by papers published in a scientific journal. J Am Soc Inf Sci Technol. 61:1377–1385. 2010.
42	Kulkarni AV, Aziz B, Shams I and Busse JW: Author self-citation in the general medicine literature. PLoS One. 6:e208852011.
43	Maraldo MV, Brodin NP, Aznar MC, et al: Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol. 24:2113–2118. 2013.
44	Darby SC, Ewertz M, McGale P, et al: Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 368:987–998. 2013.
45	Padovani L, André N, Constine LS and Muracciole X: Neurocognitive function after radiotherapy for paediatric brain tumours. Nat Rev Neurol. 8:578–588. 2012.